Company Profile
Ramat Gan, Israel
XTL Biopharmaceuticals Ltd., a biopharmaceutical company provides the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda R&D Company Limited for the research, development, and commercialization of hCDR1 for various indications. Incorporated in 1993 and headquartered in Ramat Gan, Israel, XTL Biopharmaceuticals was formerly known as Xenograft Technologies Ltd. before rebranding in July 1995.